Connect Biopharma Holdings (CNTB) has released an update.
Connect Biopharma Holdings has announced a strategic pivot towards the U.S. market, appointing new leadership and planning to scale back its operations in China. With a solid cash position of $110.2 million, the company is set to sustain its operations well into the first half of 2027. This transition includes a keen focus on advancing rademikibart, a potential treatment for inflammatory diseases, following positive feedback from the FDA on its clinical programs.
For further insights into CNTB stock, check out TipRanks’ Stock Analysis page.
